Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 6/20 | 0.58 |
| ▸ | MMP3 | P08254 | 2/20 | 0.58 |
| ▸ | MMP2 | P08253 | 1/20 | 0.58 |
| ▸ | MMP7 | P09237 | 1/20 | 0.58 |
| ▸ | MMP8 | P22894 | 1/20 | 0.58 |
| ▸ | CCR2 | P41597 | 12/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20211170 | 1.00 | MMP1 (0.58) | MMP1MMP3MMP2MMP7MMP8 | |
| SCHEMBL18467797 | 1.00 | MMP1 (0.58) | MMP1MMP3MMP2MMP7MMP8 | |
| SCHEMBL17683900 | 1.00 | MMP1 (0.58) | MMP1MMP3MMP2MMP7MMP8 | |
| Hydrochloric Acid SCHEMBL17685539 | 0.99 | MMP1 (0.57) | MMP1MMP3MMP2MMP7MMP8 | |
| Hydrochloric Acid SCHEMBL25344436 | 0.83 | CCR2 (0.60) | MMP1MMP3MMP2MMP7MMP8 | |
| Hydrochloric Acid SCHEMBL25344446 | 0.83 | CCR2 (0.60) | MMP1MMP3MMP2MMP7MMP8 | |
| Hydrochloric Acid SCHEMBL25344442 | 0.83 | CCR2 (0.60) | MMP1MMP3MMP2MMP7MMP8 | |
| SCHEMBL12875983 | 0.82 | CCR2 (0.64) | MMP1MMP3MMP2MMP7MMP8 | |
| SCHEMBL12155589 | 0.82 | CCR2 (0.64) | MMP1MMP3MMP2MMP7MMP8 | |
| SCHEMBL7372465 | 0.78 | MMP1 (0.66) | MMP1MMP3MMP2MMP7MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3009425-B1 | ALPHA-OXOACYLAMINOCAPROLACTAM | SEIKAGAKU KOGYO CO LTD (JP) | 2018-06-06 | — | — | EP | disclosed |
| EP-3009425-B1 | ALPHA-OXOACYLAMINOCAPROLACTAM | SEIKAGAKU KOGYO CO LTD (JP) | 2018-06-06 | — | — | EP | disclosed |
| EP-3009444-B1 | ALPHA-OXOACYL AMINO-CAPROLACTAM DERIVATIVE | SEIKAGAKU KOGYO CO LTD (JP) | 2017-12-20 | — | — | EP | disclosed |
| EP-3009444-B1 | ALPHA-OXOACYL AMINO-CAPROLACTAM DERIVATIVE | SEIKAGAKU KOGYO CO LTD (JP) | 2017-12-20 | — | — | EP | disclosed |
| US-9636346-B2 | Alpha-oxoacyl amino-caprolactam derivative | SEIKAGAKU CORPORATION (JP) | 2017-05-02 | — | — | US | disclosed |
| US-9636346-B2 | Alpha-oxoacyl amino-caprolactam derivative | SEIKAGAKU CORPORATION (JP) | 2017-05-02 | — | — | US | disclosed |
| US-9562042-B2 | α-oxoacyl amino-caprolactam | SEIKAGAKU CORPORATION (JP) | 2017-02-07 | — | — | US | disclosed |
| US-9562042-B2 | α-oxoacyl amino-caprolactam | SEIKAGAKU CORPORATION (JP) | 2017-02-07 | — | — | US | disclosed |
| US-20160375031-A1 | ALPHA-OXOACYL AMINO-CAPROLACTAM DERIVATIVE | SEIKAGAKU KOGYO CO LTD (JP) | 2016-12-29 | — | — | US | disclosed |
| US-9481707-B2 | α-oxoacyl amino-caprolactam derivative | SEIKAGAKU CORPORATION (JP) | 2016-11-01 | — | — | US | disclosed |
| US-9481707-B2 | α-oxoacyl amino-caprolactam derivative | SEIKAGAKU CORPORATION (JP) | 2016-11-01 | — | — | US | disclosed |
| US-20160137691-A1 | ALPHA-OXOACYL AMINO-CAPROLACTAM DERIVATIVE | SEIKAGAKU CORPORATION (JP) | 2016-05-19 | — | — | US | disclosed |
| US-20160137691-A1 | ALPHA-OXOACYL AMINO-CAPROLACTAM DERIVATIVE | SEIKAGAKU CORPORATION (JP) | 2016-05-19 | — | — | US | disclosed |
| US-20160130266-A1 | ALPHA-OXOACYL AMINO-CAPROLACTAM BODY | SEIKAGAKU CORPORATION (JP) | 2016-05-12 | — | — | US | disclosed |
| US-20160130266-A1 | ALPHA-OXOACYL AMINO-CAPROLACTAM BODY | SEIKAGAKU CORPORATION (JP) | 2016-05-12 | — | — | US | disclosed |
| EP-3009425-A1 | ALPHA-OXOACYL AMINO-CAPROLACTAM BODY | Seikagaku Corporation (JP) | 2016-04-20 | — | — | EP | disclosed |
| EP-3009444-A1 | ALPHA-OXOACYL AMINO-CAPROLACTAM DERIVATIVE | Seikagaku Corporation (JP) | 2016-04-20 | — | — | EP | disclosed |
| EP-3009444-A1 | ALPHA-OXOACYL AMINO-CAPROLACTAM DERIVATIVE | Seikagaku Corporation (JP) | 2016-04-20 | — | — | EP | disclosed |
| EP-3009425-A1 | ALPHA-OXOACYL AMINO-CAPROLACTAM BODY | Seikagaku Corporation (JP) | 2016-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160375031-A1 | ALPHA-OXOACYL AMINO-CAPROLACTAM DERIVATIVE | OGFRL1, ARGLU1, COL1A1 | MMP1 605/4885MMP3 1193/4885MMP2 929/4885 |
| US-20160137691-A1 | ALPHA-OXOACYL AMINO-CAPROLACTAM DERIVATIVE | COL2A1, ARGLU1, COL1A1 | MMP1 798/4885MMP3 1587/4885MMP2 1137/4885 |
| US-20160130266-A1 | ALPHA-OXOACYL AMINO-CAPROLACTAM BODY | ANPEP, COL2A1, PTMS | MMP1 838/4885MMP3 1149/4885MMP2 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.